BioSpace News Archive

Movano Health (Nasdaq: MOVE) announced that it successfully submitted updated pivotal clinical trial results as well as proof of enhanced medical device usability on April 22, 2024 to the U.S. Food and Drug Administration (FDA) as part of its 510(k) filing for the Company’s first commercial medical device, the Evie Med Ring pulse oximeter.

Stevanato Group S.p.A., a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced its financial results for the first quarter of 2024.

Merck, known as MSD outside of the United States and Canada, announced that the Phase 3 KEYNOTE-B21 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy as adjuvant treatment, with or without radiotherapy, did not meet its primary endpoint of disease-free survival for the treatment of patients with newly diagnosed, high-risk endometrial cancer after surgery with curative intent.

Mersana Therapeutics, Inc. provided a business update and reported financial results for the first quarter ended March 31, 2024.

Eledon Pharmaceuticals, Inc. announced that the Company will participate in the American Transplant Congress taking place in Philadelphia, PA from June 1-5, 2024.

ICON plc, a world-leading healthcare intelligence and clinical research organisation, releases its ICON Cares 2023 Report.

Mallinckrodt plc, a global specialty pharmaceutical company, reported its financial results for the first quarter ended March 29, 2024.

ProQR Therapeutics NV. reported its financial and operating results for the first quarter ended March 31, 2024, and provided a business update.

Arecor Therapeutics plc announced a research collaboration with Medtronic plc, a global leader in healthcare technology, to develop a novel, high concentration, thermostable insulin for use by Medtronic’s Diabetes business in a next-generation implantable pump.

Renalytix plc announces that it will report its third quarter fiscal year 2024 financial results on Wednesday, May 15, 2024 before U.S. market open.